Radioiodine treatment of differentiated thyroid cancer related to guidelines and scientific literature

Publication date: Available online 1 March 2019Source: Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)Author(s): M. Estorch, M. Mitjavila, M.A. Muros, E. Caballero, on behalf of the Grupo de Trabajo de Endocrinología de la SEMNIMAbstractIn differentiated thyroid cancer (DTC), radioiodine is administered to eliminate residual normal thyroid tissue after thyroidectomy (ablative treatment), to treat residual microscopic disease (adjuvant treatment), and to treat macroscopic or metastatic disease. Currently, treatment of DTC with 131I is still a matter of controversy due to the absence of prospective clinical trials assessing its benefit in terms of overall survival and recurrence-free interval. The current recommendations of the experts are based on observational retrospective data and on their interpretation of the literature. Pending the results of the prospective trials that are currently underway, the use of 131I seems to be justified not only in high-risk patients, but also in intermediate-risk and low-risk patients. The guidelines of The American and British Thyroid Association, European and American Societies of Nuclear Medicine, The European Consensus Group and the latest edition of National Comprehensive Cancer Network (NCCN) were considered in drawing up this continuing education document, we also undertook a review of the related scientific literature.ResumenEn el cáncer diferenciado de tiroides (CDT), el tratamiento con 131I se administra...
Source: Revista Espanola de Medicina Nuclear e Imagen Molecular - Category: Nuclear Medicine Source Type: research